Nonalcoholic fatty liver disease (NAFLD) is a prevalent and complex disease that confers a high risk of severe liver disorders. Despite such public and clinical health importance, very few effective therapies are currently available for NAFLD. We report a protective function and the underlying mechanism of dual-specificity phosphatase 14 (DUSP14) in NAFLD and related metabolic disorders. Insulin resistance, hepatic lipid accumulation, and concomitant inflammatory responses, key pathological processes involved in NAFLD development, were significantly ameliorated by hepatocyte-specific DUSP14 overexpression (DUSP14-HTG) in high-fat diet (HFD)-induced or genetically obese mouse models. By contrast, specific DUSP14 deficiency in hepatocytes (DUSP14-HKO) aggravated these pathological alterations. We provided mechanistic evidence that DUSP14 directly binds to and dephosphorylates transforming growth factor b-activated kinase 1 (TAK1), resulting in the reduced activation of TAK1 and its downstream signaling molecules c-Jun N-terminal kinase 1 (JNK), p38, and nuclear factor kappa B NF-jB. This effect was further evidenced by the finding that inhibiting TAK1 activity effectively attenuated the deterioration of glucolipid metabolic phenotype in DUSP14-HKO mice challenged by HFD administration. Furthermore, we identified that both the binding domain and the phosphatase activity of DUSP14 are required for its protective role against hepatic steatosis, because interruption of the DUSP14-TAK1 interaction abolished the mitigative effects of DUSP14. Conclusion: Hepatocyte DUSP14 is required for maintaining hepatic metabolic homeostasis and for suppressing inflammation, a novel function that relies on constraining TAK1 hyperactivation. (HEPATOLOGY 2018;67:1320-1338.
N onalcoholic fatty liver disease (NAFLD) is a prevalent and complex disease that arises from an imbalance between lipid accumulation and removal. (1) NAFLD is considered to be a hepatic manifestation of metabolic syndrome (2) in which insulin resistance, inflammation, hepatic glucose and lipid metabolic disorders coexist and act as intertwined causes and complications of the disease, Abbreviations: aa, amino acid; 5Z-7-ox, 5Z-7-oxozeaenol; Ad, adenoviral; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve; cDNA, complementary DNA; DMSO, dimethyl sulfoxide; DUSP14, dual-specificity phosphatases 14; ELISA, enzyme-linked immunosorbent assay; ERK, extracellular signal-regulated kinase; G6PC, glucose-6-phosphatase catalytic subunit; GFP, green fluorescent protein; GSK3b, glycogen synthase kinase 3; GTT, glucose tolerance test; H&E, hematoxylin and eosin; HFD, high-fat diet; HKO, hepatocyte-specific knockout; HOMA-IR, homeostasis model assessment of insulin resistance; HTG, hepatocyte-specific transgenic; IKKb, IjB kinase b; IL, interleukin; IRS1, insulin receptor substrate 1; ITT, insulin tolerance test; JNK, c-Jun N-terminal kinase 1; mRNA, messenger RNA; NAFLD, nonalcoholic fatty liver diseases; NC, normal chow; NEFA, nonesterified fatty acid; NF-jB, nuclear factor kappa B; NTG, nontransgenic; PAS, periodic acid-Schiff; PCR, polymerase chain reaction; PEPCK, phosphoenolpyruvate carboxykinase; SD, standard deviation; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TAK1, transforming growth factor b-activated kinase 1; TC, total cholesterol; TG, triglyceride; TNF-a, tumor necrosis factor a.
thereby accelerating its progression. (3, 4) Accumulating evidence indicate that NAFLD not only promotes the development of liver disorders of varying severityincluding steatohepatitis, cirrhosis and, ultimately, hepatocellular carcinoma-but also confers an increased risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. (5, 6) Unfortunately, therapies aimed at alleviating the heavy burden of NAFLD have advanced at a slow pace, (7) likely due to our insufficient understanding of the signaling pathways underlying NAFLD pathogenesis. Therefore, exploration of the pivotal molecular mechanisms that contribute to the onset and progression of NAFLD and related metabolic disorders is urgently needed.
Dual-specificity phosphatase 14 (DUSP14) is a ubiquitously expressed phosphatase (8) containing a highly conserved C-terminal catalytic domain that confers its phosphatase activity. (9) DUSP14 was initially defined as a novel protein that dephosphorylates extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase 1(JNK), and p38, (10) through which it participates in the negative regulation of pancreatic b cell proliferation and gastrointestinal cancer cells apoptosis. (11, 12) Additionally, the modulating effects of DUSP14 on immune responses can also be ascribed to its phosphatase activity on MAPK substrates. (10, 13, 14) Given that various members of the MAPK signaling axis have been documented as potent regulators of insulin signal transduction, glucose and lipid metabolism and metaflammation during hepatic steatosis, (15) (16) (17) DUSP14 may feasibly function as a critical regulator of the pathogenesis of hepatic steatosis and related metabolic disorders. Nevertheless, elucidating the actual effects and specific activity of DUSP14 will require further investigation.
The present study was conducted to test our hypothesis regarding the regulatory role of DUSP14 in hepatic steatosis and related metabolic disorders by deleting or enhancing the expression of DUSP14 in a mouse model. The results revealed that DUSP14 can significantly ameliorate high-fat diet (HFD)-mediated or genetically induced insulin resistance, hepatic steatosis, and concomitant inflammation. Furthermore, this newly identified function of DUSP14 requires its direct interaction with transforming growth factor bactivated kinase 1 (TAK1) and the subsequent inhibition of TAK1 and its downstream signaling pathways.
Materials and Methods

ANIMAL MODELS
supplied to mice continuously for 12 weeks to construct NAFLD model and control mice, respectively. All mice had free access to food and water. Body weights and fasting blood glucose and insulin levels were examined every 2 weeks.
Hepatocyte-specific conditional DUSP14 transgenic (DUSP14-HTG) mice were generated by microinjecting a reconstruct containing full-length DUSP14 complementary DNA (cDNA) after the CAG-loxP-CAT-loxP cassette into fertilized C57BL/6J embryos and crossing these mice with Alb-Cre mice (Jackson Laboratory, Bar Harbor, ME; Supporting Fig. S1A ). To create hepatocyte-specific knockout mice (DUSP14-HKO), DUSP14 flox/flox mice were (generated using the CRISPR/Cas9 system) mated with Alb-Cre mice (Supporting Fig. S1B ). By injecting AdDUSP14 (5 3 10 9 pfu) into 8-week-old ob/ob mice after NC consumption, DUSP14 overexpression ob/ob mice were generated, and ob/ob mice injected with AdGFP were used as controls. TAK1 activation was specifically inhibited through intraperitoneal administration of a specific inhibitor 5Z-7-oxozeaenol (5Z-7-ox; O9890-1 MG; Sigma) at a dose of 5 mg/kg in DUSP14 flox/flox and DUSP14-HKO mice.
HUMAN LIVER SAMPLES
Human liver samples were collected from the subjects that were included in a previous investigation. (18) Twenty-two subjects were histopathologically diagnosed with NAFLD and 15 participants were nonsteatosis controls. Fatty liver samples were acquired from NAFLD patients during the course of liver biopsy, whereas nonsteatosis liver samples were obtained from living donors who underwent liver resection to treat hepatic cyst or liver hemangioma. Informed consent was provided by every participant or their relatives. All procedures performed in this study conformed to the protocol approved by the Research Ethics Committee of Renmin Hospital of Wuhan University.
METABOLIC INDICATORS MEASUREMENTS
Fasting blood glucose levels were tested in mice that were fasted for 6 hours every 2 weeks until the 12th week using a glucometer (One Touch Ultra Easy, Life Scan, Wayne, PA), whereas fasting insulin levels were estimated using enzyme-linked immunosorbent assay (ELISA; Millipore, Billerica, MA) at the endpoint of the experiment. We conducted glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) on 6-hour-fasted animals by way of intraperitoneal injection of 1 g/kg glucose and 0.75 U/kg insulin separately. Blood glucose levels were measured 0, 15, 30, 60, and 120 minutes after injection.
LIVER LIPID, HEPATIC DAMAGE, AND SYSTEMIC INFLAMMATION PROFILES
The liver content of triglyceride (TG), total cholesterol (TC), and nonesterified fatty acid (NEFA) was evaluated using commercial kits (Wako, Osaka, Japan). A spectrophotometer (Chemix 180i, Sysmex Shanghai Ltd, Shanghai, China) was employed to measure the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) according to the operating manual. The serum levels of pro-inflammatory mediators were detected by way of ELISA.
HISTOLOGICAL ANALYSIS AND IMMUNOHISTOCHEMISTRY
The paraffin-embedded liver sections were stained with hematoxylin and eosin (H&E), and the frozen liver sections were stained with Oil Red O. To detect glycogen content, paraffin-embedded liver sections were stained with periodic acid-Schiff (PAS). Histological images were acquired with a light microscope (Olympus, Tokyo, Japan). Immunohistochemistry staining was performed to determine the expression profile of DUSP14.
PRIMARY HEPATOCYTE ISOLATION, CULTURE, AND ADENOVIRAL VECTOR INFECTION
Liver perfusion was used to isolate primary hepatocytes from the livers of 6-to 8-week-old mice as reported previously. (19) Primary hepatocytes were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a 5% CO 2 atmosphere at 378C. Before recombinant adenoviral infection, palmitate was administrated to a part of cultured hepatocytes to create an in vitro hepatic steatosis model.
WESTERN BLOTTING AND QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION
Cytosolic and nuclear proteins were extracted from liver tissue samples and hepatocytes. Next, 30 lg of protein extracts was run on sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF membrane, then incubated with the corresponding primary and secondary antibodies (Supporting Table S1 ) for visualization.
Total messenger RNA (mRNA) was isolated and cDNA was synthesized. Next, quantitative real-time polymerase chain reaction (PCR) was conducted using SYBR Green (Roche). The mRNA levels of the target genes were normalized to b-actin levels.
PLASMID CONSTRUCTS
Human DUSP14 cDNA was cloned into psi-flag-C1, pcDNA5-HA-C1, and pGEX-6p-1 plasmids to create psi-flag-DUSP14, pcDNA5-HA-DUSP14, and HA-GST-DUSP14, respectively. DUSP14 truncations were generated by PCR-amplifying psiFlag-DUSP14.
Meanwhile, psi-Flag-TAK1, pcDNA5-HA-TAK1, HA-GST-TAK1, and TAK1 truncations were generated using the same approach.
IMMUNOPRECIPITATION
To detect the DUSP14-TAK1 interaction, immunoprecipitation assays were performed in primary hepatocytes isolated from the livers of DUSP14-HTG mice and in cultured HEK293T cells cotransfected with reconstructs. The cells were then lysed and centrifuged. After that, each sample (500 lL) was incubated with protein A/G-agarose beads and primary antibodies. Cold immunoprecipitation buffer was used to wash the immunocomplexes, which were then analyzed through immunoblotting using the indicated primary antibodies and corresponding secondary antibodies.
GST PULL-DOWN ASSAY
The Escherichia coli was transformed with plasmid HA-GST-DUSP14/HA-GST-TAK1, followed by immobilization on glutathione-Sepharose 4B beads. The beads were then washed with 1 mL of phosphatebuffered saline five times and then incubated with immunopurified Flag-TAK1/Flag-DUSP14 for 4 hours at 48C, followed by washing with immunoprecipitation lysis buffer. The eluted proteins were resolved by way of SDS-PAGE and then analyzed with western blotting using anti-Flag antibodies.
STATISTICAL ANALYSIS
All data in this study are expressed as the mean 6 standard deviation (SD) and were calculated using SPSS software (version 21.0). Appropriate statistical analysis methods were used as specified in the figure legends. For comparisons between two groups, a Student two-tailed t test was used. For comparisons among multiple groups, parametric statistical analysis was performed using one-way analysis of variance, with Fisher's least significant difference for data satisfying the homogeneity of the variance or with Tamhane's T2 post hoc test for data of heteroscedasticity. P <0.05 was regarded as statistically significant.
ADDITIONAL METHODS
Detailed methods are provided in the Supporting Information.
Results
DUSP14 EXPRESSION IS DECREASED IN THE LIVERS OF NAFLD PATIENTS AND IN HFD-TREATED MICE
To investigate the precise function of DUSP14 in hepatic steatosis, we first analyzed its expression in liver samples from NAFLD patients and nonsteatosis subjects; lower DUSP14 protein levels were observed in the livers of NAFLD patients than in those of nonsteatosis donors (Fig. 1A) . Consistent with the findings in human samples, DUSP14 protein expression was dramatically down-regulated in murine livers after 12 weeks of HFD treatment (Fig. 1B) . The protein levels of DUSP14 in the livers of ob/ob mice progressively decreased from 2 to 12 weeks (Fig. 1C) . In primary hepatocytes, DUSP14 protein expression was also significantly decreased after palmitate stimulation, which was similar to the results obtained after oleic acid administration (Fig. 1D) . Furthermore, the reduction of DUSP14 expression in the livers of NAFLD patients was visualized and further confirmed using immunohistochemistry staining (Fig. 1E) . The consistent decrease in DUSP14 expression observed in the fatty livers of NAFLD patients and in mouse models suggests that DUSP14 may have a critical regulatory effect on hepatic steatosis. 
HEPATOCYTE-SPECIFIC DUSP14 OVEREXPRESSION ALLEVIATES INSULIN RESISTANCE INDUCED BY HFD
Insulin resistance is widely considered as a key pathogenic factor of NAFLD. (20) Thus, to elucidate the effects of DUSP14 on insulin sensitivity, we generated transgenic mice with hepatocyte-specific DUSP14 overexpression (DUSP14-HTG) (Supporting Fig. S2A ). All mice were administrated with NC or HFD for 12 weeks. DUSP14-HTG mice manifested decreased fasting blood glucose and insulin levels and calculated homeostasis model assessment of insulin resistance (HOMA-IR) values after HFD challenge compared with nontransgenic (NTG) controls ( Fig. 2A-C ). GTTs and ITTs revealed that DUSP14 overexpression reduced blood glucose levels and area under the curve (AUC) values in response to HFD stimulation ( Fig. 2D and E). Meanwhile, the expression levels of critical molecules in the IRS-AKT signaling pathway, which is closely associated with the pathophysiology of insulin resistance, was assessed. The results revealed increased phosphorylated IRS
Try608
, AKT Ser47 and glycogen synthase kinase 3 (GSK3b) expression induced by DUSP14 overexpression (Fig. 2F ). The increased phosphorylation of IRS at Tyr608 enhances the recruitment and activation of its downstream effector AKT. This phenomenon highly implicates improved activation of the insulin signaling pathway in DUSP14-HTG mice. Glycogen accumulation was consistently increased in the livers of DUSP14-HTG mice compared with the NTG controls, as detected by the glycogen content assay and observed in PAS staining ( Fig. 2G and Supporting Fig. S3A ), and was accompanied by the significantly blocked mRNA transcriptions of the key gluconeogenesis enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase catalytic subunit (G6PC) (Fig. 2H) . Interestingly, DUSP14-HTG mice showed lower fasting blood glucose and insulin levels than their NTG littermates after 12 weeks of NC consumption ( Fig. 2A-C ).
DUSP14 OVEREXPRESSION AMELIORATES HFD-MEDIATED HEPATIC STEATOSIS AND INFLAMMATORY RESPONSE
Ectopic lipid deposition is a key characteristic of NAFLD. After 12 weeks of HFD treatment, DUSP14 overexpression had no effect on mouse body weight gain, whereas DUSP14-HTG mice exhibited lower liver weights than those of the NTG controls (Fig. 3A,B) . The liver TG, TC, and NEFA contents were considerably reduced by DUSP14 overexpression compared with NTG controls (Fig. 3C ). In accordance with theses alterations, HFD stimulation induced steatosis and hepatocyte ballooning in the livers of NTG mice, whereas the DUSP14-HTG mice manifested a reduction of these steatotic alterations, as visualized by H&E staining. Oil Red O staining also showed reduced hepatic lipid droplets formation in DUSP14-HTG mice compared with the NTG controls (Fig.  3D) . The mRNA levels of key enzymes participating in lipid metabolism were further examined, revealing reduced mRNA levels of genes related to cholesterol synthesis (3- S3B ). Moreover, reduced TG and TC concentrations were observed in serum samples from DUSP14-HTG mice compared with NTG controls (Fig. 3E) . Because excessive lipid accumulation induces lipotoxicity leading to hepatic damage, (21) we next assessed the serum levels of ALT and AST, revealing mitigated liver injury in DUSP14-HTG mice (Fig. 3F) .
Inflammation is recognized as another hallmark of NAFLD, triggering and promoting hepatic steatosis. Therefore, we measured several inflammatory mediators, including tumor necrosis factor a (TNF-a), interleukin (IL)-1b, IL-2, IL-4, and IL-6. We found that their concentrations were down-regulated in the sera of DUSP14-HTG mice compared with NTG controls after HFD consumption (Fig. 3G) , and the TNF-a, IL-1b, and IL-6 mRNA levels in the liver were similarly altered (Fig. 3H) . We further detected the activation of the nuclear factor kappa B (NF-jB) pathway, a canonical proinflammatory signaling pathway. DUSP14 overexpression blocked NF-jB signaling activation, as indicated by the decreased phosphorylation levels of IjB kinase b (IKKb), p65, and IjBa (Fig. 3I ). This result was further validated by in vitro FIG. 2 . Hepatocyte-specific DUSP14 overexpression protects mice against insulin resistance and glucose intolerance. (A) Fasting blood glucose in DUSP14-HTG and DUSP14-NTG mice that were fasted for 6 hours every 2 weeks after NC or HFD treatment until the 12th week (n 5 10-19 per group). (B, C) Fasting insulin in serum (B) and calculated HOMA-IR values (C) in DUSP14-HTG mice and NTG controls that were fasted for 6 hours after 12 weeks of NC or HFD consumption (n 5 10-19 per group). (D,E) GTTs (1 g/ kg, glucose) (D) and ITTs (0.75 U/kg, insulin) (E) were performed on DUSP14-HTG mice and DUSP14-NTG controls in the 10th week of HFD consumption to quantify blood glucose levels (left panel), and the corresponding AUC values were calculated (right panel) (n 5 10-19 per group). (F) Representative western blots (of n 5 2 western blots for each protein) of the expression of phosphorylated and total IRS1, AKT, and GSK3b in the liver samples of DUSP14-HTG mice and NTG controls that were fasted for 6 hours after 12 weeks of HFD feeding (n 5 2 in each group without insulin stimulation, n 5 6 in each group receiving an intraperitoneal injection of 1 U/kg insulin, presented as insulin 2 and 1 at the top, respectively) (left panel). Insulin-stimulated phosphorylated protein levels were normalized to the respective total protein levels (right panel). (G,H) Total glycogen content (G) and mRNA levels of key gluconeogenesis enzymes (PEPCK and G6PC) (H) in the livers of DUSP14-HTG and DUSP14-NTG mice fed a HFD (n 5 6-8 per group). Gene expression was normalized to that of b-actin. The data are presented as the mean 6 SD.
† P < 0.05 versus the DUSP14-NTG/ NC group; *P < 0.05 versus the DUSP14-NTG/NC group; # P < 0.05 versus the DUSP14-NTG/HFD group. Significance was analyzed using one-way analysis of variance with Tamhane's T2 post hoc test (A-C) or a Student two-tailed t test (D-H).
FIG. 3 HEPATOLOGY
experiments using primary hepatocytes transfected with AdDUSP14 or AdGFP (Supporting Fig. S3C ). Intriguingly, DUSP14 overexpression also enabled the hepatocytes to maintain lipid metabolic homeostasis and prevent inflammation in the NC group (Fig. 3A- C,E-I and Supporting Fig. S3B ).
DUSP14 DEFICIENCY EXACERBATES HFD-INDUCED INSULIN RESISTANCE, HEPATIC STEATOSIS AND INFLAMMATION
Next, we generated DUSP14-HKO mice to further verify the regulatory function of DUSP14 in hepatic glucolipid metabolism (Supporting Fig. S2B ). DUSP14-HKO mice exceeded the Flox controls in terms of the increases in fasting blood glucose and insulin levels and blood glucose content in the GTTs and ITTs after HFD challenge (Fig. 4A-D) . Accordingly, DUSP14 depletion suppressed the activation of the insulin signaling pathway (Fig. 4E) . Additionally, DUSP14 ablation reduced hepatic glycogen accumulation, which was accompanied by the highly induced mRNA transcriptions of PEPCK and G6PC (Supporting Fig. S4A-C) . DUSP14-HKO mice exhibited increased liver weight gain but similar body weight gain relative to their Flox littermates after HFD consumption (Fig. 4F,G) . Furthermore, DUSP14 deficiency resulted in up-regulated hepatic lipid content (TG, TC, and NEFA) (Fig. 4H) . Consistently, H&E and Oil Red O staining revealed exacerbated steatosis and hepatocyte ballooning and increased lipid droplet deposition in the livers of DUSP14-HKO mice fed an HFD compared with Flox controls (Fig. 4I) . Consistent with the histological appearance, depleting DUSP14 in hepatocytes caused deteriorated changes in lipid metabolism-related gene expressions and worsened systemic dyslipidemia and liver injury (Supporting Fig. S4D,E and Fig. 4J ).
Furthermore, inflammatory mediator levels in the serum and the liver were elevated in HFD-fed DUSP14-HKO mice compared with Flox controls (Fig. 4K,L) . Phosphorylation of the NF-jB signaling cascade after HFD stimulation was also promoted by DUSP14 ablation, which was further confirmed by in vitro experiments (Supporting Fig. S4F,G) . In addition, impaired insulin sensitivity, aggravated hepatic steatosis, and inflammation were also observed in DUSP14-HKO mice after NC administration (Fig. 4A,B ,G,H,J-L and Supporting Fig. 4D-F) .
DUSP14 UP-REGULATION AMELIORATES GLUCOSE AND LIPID METABOLIC DISORDERS IN ob/ob MICE
To confirm the protective role of DUSP14 in metabolic disorders, we employed genetically obese mice (leptin-deficient, ob/ob mice). After 8 weeks of NC consumption, 8-week-old ob/ob mice were injected with a recombinant adenovirus for an additional 4 weeks to induce DUSP14 overexpression in their livers (obAdDUSP14) (Supporting Fig. S5A ). DUSP14 overexpression down-regulated their fasting blood glucose and insulin levels and HOMA-IR without affecting their body weight gain (Fig. 5A-D) . GTTs, ITTs, and PAS staining further emphasized improved insulin sensitivity and augmented glycogen accumulation in ob-AdDUSP14 mice compared with their genetically obese control littermates (Fig. 5E,F and Supporting Fig. S5B ). In parallel with its impact on glucose metabolism, DUSP14 upregulation also served as a vital contributor to the mitigation of liver weight gain and hepatic steatosis, as evidenced by decreased hepatic lipid content, repressed expression of genes participating in fatty acid synthesis but enhanced mRNA levels of genes involved in fatty acid b-oxidation, reduced steatotic alterations, and relieved lipid droplets Representative H&E-stained (top) and Oil Red O-stained (bottom) images of liver sections from DUSP14-HTG and DUSP14-NTG mice after HFD treatment for 12 weeks (n 5 8 images per group for each staining; scale bars: 100 lm and 50 lm, respectively). (E-G) TG and TC concentrations (E), ALT and AST levels (F), and TNF-a, IL-1b, IL-2, IL-4, and IL-6 concentrations (G) in the serum of DUSP14-NTG and DUSP14-HTG mice after 12 weeks of NC or HFD administration (n 5 10-19 per group). (H) Relative mRNA levels of TNF-a, IL-1b and IL-6 in the liver samples of DUSP14-HTG and DUSP14-NTG mice fed NC or an HFD (n 5 6-8 samples per group), b-actin was used as the loading control. (I) Representative western blots (of n 5 2 western blots for each protein) for the expression of phosphorylated and total IKKb, P65, and IjBa in liver samples from DUSP14-HTG and DUSP14-NTG mice fed NC or HFD (n 5 4 mice per group) (right panel). The phosphorylated protein levels were normalized to the respective total protein levels (left panel). The data are presented as the mean 6 SD. † P < 0.05 versus the DUSP14-NTG/NC group; *P < 0.05 versus the DUSP14-NTG/NC group; # P < 0.05 versus the DUSP14-NTG/HFD group. Significance was determined by one-way analysis of variance with Tamhane's T2 post hoc test (A-C,E-I). accumulation in the livers of ob-AdDUSP14 mice (Fig.  5G-J) . Collectively, these findings strongly indicate that DUSP14 overexpression can alleviate genetically induced imbalances in glucolipid metabolism.
DUSP14 MODULATES ACTIVATION OF THE TAK1-DEPENDENT SIGNALING PATHWAY
Next, we sought to elucidate the underlying mechanism by which DUSP14 modulates hepatic steatosis. DUSP14 possesses phosphatase activity toward MAPK substrates, (10) which are closely associated with various metabolic events. (22) Thus, we focused on examining the contribution of MAPK signaling to the regulatory effects of DUSP14. Under NC conditions, the phosphorylated levels of JNK1/2 and p38 were slightly reduced in DUSP14-HTG mice but elevated in DUSP14-HKO mice (Fig. 6A,B) . Meanwhile, 12 weeks of HFD consumption led to pronounced increases in the phosphorylation levels of MEK1/2, ERK1/2, JNK1/2, and p38. Nevertheless, only the phosphorylated levels of JNK1/2 and p38 were notably dampened in DUSP14-HTG mice but further enhanced in DUSP14-HKO mice (Fig.  6A,B) . Furthermore, in vitro experiments using primary hepatocytes transfected with AdDUSP14 or Adsh-DUSP14 and vehicle controls provided consistent results (Supporting Fig. S6A,B) .
To identify how DUSP14 affects JNK1/2 and p38, we examined the expression levels of several MAP3Ks (ASK1, TAK1, TBK1, and MEKK1), which are wellestablished upstream kinases of JNK1/2 and p38. (23) Intriguingly, among all of the tested MAP3Ks, TAK1 activation was reduced in DUSP14-HTG mice but enhanced in DUSP14-HKO mice after NC consumption (Fig. 6C,D) . More importantly, after HFD stimulation, increases in TAK1 phosphorylation were mitigated in case of hepatocyte DUSP14 overexpression but further elevated in the DUSP14-HKO group, whereas other MAP3Ks displayed no detectable alterations according to fluctuations in DUSP14 levels (Fig.  6C,D) . This result was further confirmed by the findings obtained in in vitro experiments (Supporting Fig.  S6C,D) . Therefore, these results provide compelling evidence that DUSP14 is capable of modulating the activation of the TAK1-dependent signaling pathway.
DUSP14 DIRECTLY INTERACTS WITH AND DEPHOSPHORYLATES TAK1
Considering the inhibitory effect of DUSP14 on TAK1 phosphorylation, we were intrigued to elucidate the mechanism underlying their connection. Coimmunoprecipitation experiments were performed in primary hepatocytes isolated from the liver tissues of DUSP14-HTG mice and in HEK293T cells to address this question; the results revealed that DUSP14 can physically interact with TAK1 and vice versa (Fig. 7A) , which was further confirmed by GST pull-down assays (Fig. 7B) . Next, DUSP14 and TAK1 were truncated into a diverse series of segments to further investigate the definitive binding domains between these two molecules (Fig. 7C) . Mapping experiments revealed that the 1-90 aa domain of DUSP14 was required for its binding to TAK1, while the 1-300 aa domain of TAK1 was necessary for its interaction with DUSP14 (Fig. 7D) . DUSP14 is a multitarget phosphatase, (10) and TAK1 phosphorylation is essential for its activation. (24) Therefore, to verify the possibility that DUSP14 represses TAK1 activation via dephosphorylation, we transfected L-02 cells with DUSP14 or DUSP14 mutants. After palmitate stimulation, DUSP14 overexpression reduced the phosphorylation of TAK1 and its downstream molecules JNK1/2, p38, IKKb, and IjBa compared with empty vector controls. However, the conversion of cysteine 111 to serine (C111S), which disrupted its phosphatase activity, led to the inability of DUSP14 to produce such inhibitory effects, identical to the results obtained for cells that transfected with DUSP14 lacking the 1-90 aa domain (D1-90aa) (Fig. 7E) . DUSP14 overexpression acutely ameliorated lipid accumulation in hepatocytes after palmitate administration, whereas the DUSP14 mutants (C111S, D1-90aa) led to an extent of hepatocellular lipid deposition comparable to that of the empty vector controls, as visualized by Oil Red O staining (Fig.  7F) and measured by the intracellular TG assay (Fig.  7G) . Accordingly, DUSP14 overexpression efficiently suppressed the expression of genes that control fatty acid synthesis but increased the mRNA levels of genes involved in fatty acid b-oxidation after palmitate stimulation, whereas DUSP14 mutations (C111S, D1-90aa) failed to exert such effects on gene expression (Fig. 7H ).
TAK1 INHIBITION IS REQUIRED FOR THE AMELIORATIVE EFFECT OF DUSP14 ON INSULIN RESISTANCE, HEPATIC STEATOSIS, AND INFLAMMATION
Based on the observations that DUSP14 ameliorated lipid accumulation by directly interacting with and dephosphorylating TAK1 in L-02 cells, we sought to perform in vivo experiments to further validate this finding. Therefore, we intraperitoneally injected a TAK1 inhibitor (5Z-7-ox) in DUSP14-Flox and DUSP14-HKO mice for an additional 4 weeks after 8 weeks of HFD treatment to restrain TAK1 activation, whereas dimethyl sulfoxide (DMSO) was administrated to their littermates as controls (Supporting Fig. S7A ). After being subjected to 5Z-7-ox administration, DUSP14-Flox mice exhibited improved insulin sensitivity and glucolipid metabolic homeostasis, relieved hepatic steatosis, and attenuated inflammation compared with their DMSO-treated control littermates (Fig. 8A-L) . More importantly, TAK1 inhibition effectively reduced the increases in fasting blood glucose and insulin levels and ameliorated insulin resistance, all of which resulted from DUSP14 ablation in hepatocytes ( Fig. 8A-E) . Together with its validated impact on glucose metabolism, TAK1 inhibition notably mitigated the deterioration of liver weight gain, ectopic hepatic lipid accumulation, dyslipidemia, liver damage, and inflammation in DUSP14-HKO mice (Fig.  8F-L and Supporting Fig. S7B) . Hence, the beneficial effects of DUSP14 on hepatic steatosis rely on the suppression of TAK1 activation.
Discussion
As a prevalent and complex disease, NAFLD is a leading precursor of severe liver disorders. (25) Despite such public and clinical health importance, very few effective therapies are currently available for NAFLD. NAFLD development involves a complex interplay of multiple processes, including obesity, insulin resistance, and various inflammatory responses.
(4) Herein, we identified the alleviative effects of DUSP14 on insulin resistance, hepatic steatosis, and inflammation.
FIG. 7. DUSP14 directly interacts with and dephosphorylates TAK1. (A)
The DUSP14-TAK1 interaction was examined using coimmunoprecipitation experiments in HEK293T cells cotransfected with Flag-tagged DUSP14 and HA-tagged TAK1 (left and middle panels), and in primary hepatocytes isolated from the liver tissues of DUSP14-HTG mice (right panel). (B) GST pull-down assays of Flag-tagged DUSP14 with HA-GST or HA-GST-tagged TAK1 (top) and Flag-tagged TAK1 with HA-GST or HA-GST-tagged DUSP14 (bottom) were performed to further confirm the direct binding between DUSP14 and TAK1 (C) Diagrams of the four truncated DUSP14 mutants and five truncated TAK1 mutants. (D) Full-length DUSP14 and TAK1 and their truncated mutants were co-immunoprecipitated with anti-Flag antibodies, followed by immunoblotting with anti-HA antibodies to investigate the precise domains of both DUSP14 and TAK1 responsible for their physical binding. (E-H) Representative western blots (left panel) and quantification (right panel) of the expression levels of phosphorylated TAK1, JNK1/2, p38, IKKb, and IjBa and total TAK1 and IjBa (E). Oil Red O-stained images (scale bar: 30 lm) (F), intracellular TG levels (G), and mRNA levels of fatty acids metabolismrelated genes (H) in L-02 cells that were transfected with an empty vector, Flag-tagged DUSP14 (FL) or Flag-tagged DUSP14 mutants (D1-90aa, C111S) and administered with palmitate for 12 hours (n 5 6 samples per group). Western blots are representative of n 5 3 independent experiments. All data are expressed as the mean 6 SD. *P <0.05 versus the empty vector/palmitate group. n.s., no significant difference. Significance was determined by one-way analysis of variance with Fisher's least significant difference (E,G) or one-way analysis of variance with Tamhane's T2 post hoc test (H). Mechanistically, DUSP14 directly binds to and dephosphorylates TAK1, thus inhibiting the activation of TAK1 and its downstream JNK, p38, and NF-jB pathways. Moreover, the regulatory effects of DUSP14 on metabolic and inflammatory phenotypes under basal conditions reinforce the physiological significance of its ability to prevent uncontrolled TAK1 activation. NAFLD regulation is complicated and includes a complex molecular network, among which TAK1, a stress-inducible MAP3K, has been targeted as a critical factor. Recent studies have depicted a potent detrimental role of TAK1 in various maladies, including cardiac hypertrophy, (26) metabolic disorders, apoptosis in the liver, (27, 28) and ischemic/reperfusion injuries in hepatocytes. (29) Furthermore, our results showed that suppressing TAK1 activation with a specific inhibitor ameliorated insulin resistance, hepatic steatosis, and inflammation in mice fed a HFD diet, highlighting the causal role of TAK1 hyperactivation in glucolipid metabolic dysfunction in the liver. Intriguingly, other studies have verified an essential role of TAK1 in maintaining functional homeostasis of the liver, as indicated by exacerbated lipid metabolic disorders (30) and hepatic tumorigenesis (31) in TAK1-HKO mice. This inconsistency may be due to the diverse functionality of TAK1 in basal physiological processes. TAK1 regulates a wide array of cellular programs, such as immune responses, (32) cell survival, and death.
Hence, we postulate that the activation status of TAK1 must be controlled within an appropriate range to maintain the metabolic equilibrium. In this study, we identified that DUSP14 plays a critical role in antagonizing TAK1 hyperactivation, thereby maintaining liver homeostasis and generating protective effects against hepatic steatosis. We demonstrated that DUSP14 exhibits its inhibition effects by directly interacting with TAK1, which depends on the 1-90 aa domain of DUSP14 and the 1-300 aa domain of TAK1. More significantly, we identified that DUSP14 exerts its protective function by constraining the activation of TAK1 and its downstream molecules, in which the phosphatase activity of DUSP14 on TAK1 is consistent with previous findings in immune cells. (13) Furthermore, we found that the catalytic domain mutations and the 1-90 aa deletion abrogated the dephosphorylating capacity of DUSP14 on TAK1. Consequently, DUSP14 mutants that were introduced into L-02 cells lost their capability to restrain TAK1 activation, leading to an exacerbated extent of hepatocellular lipid accumulation after palmitate stimulation, compared with AdDUSP14-transfected cells. This finding indicates the indispensability of the binding domain and the dephosphorylating capacity of DUSP14 for its protective role against hepatic steatosis.
Our in vivo and in vitro experiments consistently showed that DUSP14 reduced the phosphorylation levels of JNK1/2, p38, and molecules in the NF-jB pathway by dephosphorylating TAK1, which acts as a crucial upstream kinase of these signaling cascades. (29) The regulatory effect of DUSP14 on these MAPKs observed in our study has cell type-and stimulusspecificity compared with previous studies. (9, 14) As a well-known downstream effector of TAK1, JNK1 plays a critical role in regulating the patterns of IRS Ser/Tyr phosphorylation, which could profoundly influence insulin sensitivity. (33, 34) JNK1 potently promotes the phosphorylation of IRS1 at Ser307, and subsequently down-regulates Tyr608 phosphorylation, which reduces the coupling between the insulin receptor and IRS1 and decreases AKT phosphorylation, leading to the suppressed efficacy of insulin signal transduction. (35, 36) Our results revealed that DUSP14 overexpression efficiently blocked the HFD-induced , insulin) (E) were performed to evaluate insulin sensitivity in mice from the indicated groups (left panel), and AUC values were calculated correspondingly (right panel) (n 5 10 per group). (F-H) Changes in body weights (F), liver weights (G), hepatic lipid contents (TG, TC, and NEFA) (H) in DUSP14-Flox and DUSP14-HKO mice with DMSO or 5Z-7-ox treatment fed with a HFD (n 5 10 per group). (I) Representative H&E-stained (top) and Oil Red Ostained (bottom) images of liver sections from DUSP14-HKO and DUSP14-Flox mice that received DMSO or 5Z-7-ox treatment in response to HFD consumption (scale bar: 50 lm; n 5 5 images for each group). (J-L) Levels of lipids (TG and TC) (J), liver enzymes (ALT and AST) (K) and proinflammatory mediators (TNF-a, IL-1b, IL-2, IL-4, and IL-6) (L) in the serum of HFD-fed DUSP14-Flox and DUSP14-HKO mice administrated with DMSO or 5Z-7-ox (n 5 10 per group). All data are expressed as the mean 6 SD. *P < 0.05 versus the DUSP14-Flox/DMSO group; # P < 0.05 versus the DUSP14-HKO/DMSO group. n.s., no significant difference. Significance was determined using one-way analysis of variance with Fisher's least significant difference (A,F), or oneway analysis of variance with Tamhane's T2 post hoc test (B-E,G,H,J-L).
phosphorylation of JNK1, which subsequently promoted the IRS1 protein to undergo phosphorylation at Tyr608, enabling the recruitment and activation of its downstream effectors and thus propagating insulin signaling. Hence, DUSP14 constrains the activation of the TAK1-JNK1 axis to regulate Ser/Tyr IRS1 phosphorylation and thereby improves insulin sensitivity. Furthermore, with the development of hepatic insulin resistance in NAFLD, (4) insulin fails to suppress the FoxO1-PEPCK pathway, while activation of the mTOR-SREBP-1c pathway is presumably preserved, which then preferentially activates the transcription of lipogenic genes, resulting in enhanced lipogenesis and excessive lipid accumulation in the liver. (37, 38) In addition, the JNK1 pathway is directly involved in the deterioration of hepatic steatosis (35) and the regulation of PPARa mRNA expression. (39) In the present study, hepatocyte-specific DUSP14 overexpression restrained JNK1 pathway activation, which not only improved insulin sensitivity but also repressed lipogenic gene expressions and alleviated lipid accumulation in the liver. Taken together, the ability of DUSP14 to ameliorate insulin insensitivity and hepatic steatosis relies primarily on the suppression of TAK1-JNK1 activation.
Inflammation has been proposed as a crucial player in the pathogenesis of metabolic disorders. Inflammatory signaling, such as the JNK and NF-jB pathways, are one of numerous complex links connecting inflammation with metabolic regulation. (40, 41) The JNK and NF-jB pathways are well-documented master switches in controlling the production of a host of proinflammatory mediators, including TNF-a, IL-1b, and IL-6, (42, 43) and immune cytokines, such as IL-2 and IL-4. (10, 44) DUSP14 overexpression effectively blocked the hyperactivation of TAK1 and its downstream JNK and NF-jB pathways and thereby reduced the levels of these proinflammatory cytokines both systematically and in the liver. These proinflammatory mediators not only contribute to liver damage and dysfunction (45) but also disrupt insulin function and drive insulin resistance together with the activated JNK and NF-jB pathways, (40, 46) linking inflammation with metabolic disturbance. Therefore, this alleviated inflammatory phenotype may also confer a certain extent of contribution to the improved glucolipid metabolism in DUSP14-HTG mice.
In conclusion, we identified DUSP14 as a significant regulator of hepatic steatosis. DUSP14 directly binds to and dephosphorylates TAK1, which inhibits the activation of TAK1 and its downstream JNK1, p38, and NF-jB pathways, resulting in the amelioration of insulin resistance, hepatic steatosis, and inflammation induced by HFD consumption or a genetic defect, as evidenced by the in vivo and in vitro findings presented herein. This study highlights DUSP14 as a regulator in NAFLD pathogenesis and a worthy target for the development of promising therapeutic strategies in the future.
